Search Browse Earnings

GT Biopharma, Inc.

Nasdaq:GTBP

Pharmaceutical Preparations·SAN FRANCISCO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

GT Biopharma, Inc. — SlamSEC

Revenue

$0

FY 2020

Adj. EBITDA

-$14.4M

FY 2025

Net Income

-$13.2M

FY 2025

EPS (Diluted)

-$6.94

FY 2025

Stock Price

$0.44

+6.0%

2026-03-11

52W Range

$0.39 – $3.85

P/E Ratio

-0.1x

Market Cap

$1.6M

Cash

$4.0M

FY 2025

Total Debt

—

Net Cash

$4.0M

FY 2020

Enterprise Value

-$2.4M

Debt / EBITDA

0.3x

FY 2020

EV / EBITDA

0.2x

Employees

—

CEO

Breen Michael Martin

CFO

Urban Alan Louis